 12-month clinical study Duchenne muscular dystrophy carried double-blind trial allopurinol therapy. disease monitored assessment muscle power function, pulmonary function tests, electrocardiography. Biochemical assessments made plasma creatine kinase, pyruvate kinase, uric acid, urinary excretion 3-methylhistidine creatinine. Allopurinol alter progression disease.